作者: Jenny H. Zheng , Jack Cook , Melanie R. Nicol , Abhay Joshi , Matthew L. Rizk
DOI: 10.1002/CPT.1993
关键词:
摘要: Chloroquine and hydroxychloroquine are quinoline derivatives used to treat malaria. To date, these medications not approved for the treatment of viral infections, there no well-controlled, prospective, randomized clinical studies or evidence support their use in patients with coronavirus disease 2019 (COVID-19). Nevertheless, chloroquine being studied alone combination other agents assess effectiveness prophylaxis COVID-19. The effective any medication involves an understanding its pharmacokinetics, safety, mechanism action. This work provides basic pharmacology information relevant planning initiating COVID-19 hydroxychloroquine, summarizes safety data from healthy volunteer studies, phase II II/III uncomplicated malaria, including a study pediatric following administration azithromycin combination. In addition, this presents describing proposed mechanisms action against severe acute respiratory distress syndrome coronavirus-2 efficacy date.